• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Stroke Subtypes and Risk Factors in Saudi Arabia (P1.124)
CONCLUSION: Non-cardioembolic disease was the overwhelming stroke mechanism in this middle-eastern cohort with only 4[percnt] of patients have cardioembolic stroke, in comparison to roughly 20[percnt] reported in Western cohorts. In part, these differences may be explained by deficient prolonged cardiac monitoring. However the high prevalence of atherothrombotic risk factors and overrepresentation of non-cardioembolic stroke suggests a need to optimize atherothrombotic stroke risk factor management within our populationDisclosure: Dr. Al Harbi has nothing to disclose. Dr. Shoamanesh has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Al Harbi, A., Shoamanesh, A. Tags: Cerebrovascular Disease: Epidemiology Source Type: research

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news